“…The results showed that C16:0, C18:0, C20:0, and C24:1 ceramides were significantly elevated in the serum of lupus nephritis patients when compared to healthy controls (p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively), and to SLE patients without renal impairment (p < 0.01, p < 0.001, p < 0.001, and p < 0.001, respectively). Since circulating ceramides are carried on lipoproteins, plasma C16:0, C18:0, C20:0, and C24:1 ceramides were, as expected, also significantly elevated in lupus nephritis patients when compared to the healthy controls as well as SLE patients without renal impairment (53). Plasma dihydroceramide C24:1 was also elevated (p < 0.05) in lupus nephritis patients in comparison to SLE patients, suggesting that C24:1 dihydroceramide, and C16:0, C18:0, C20:0, and C24:1 ceramides could be useful in differentiating SLE patients with renal damage from those without (53).…”